WGS Stock Summary and Trading Ideas (Genedx Holdings Corp. - Class A | NASDAQ:WGS)

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Genedx Holdings Corp. - Class A trades on the NASDAQ stock market under the symbol WGS.

As of February 20, 2026, WGS stock price declined to $89.05 with 78,753 million shares trading.

WGS has a beta of 1.23, meaning it tends to be more sensitive to market movements. WGS has a correlation of 0.04 to the broad based SPY ETF.

WGS has a market cap of $2.57 billion. This is considered a Mid Cap stock.

Last quarter Genedx Holdings Corp. - Class A reported $117 million in Revenue and $.49 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.12.

In the last 3 years, WGS traded as high as $170.87 and as low as $1.16.

The top ETF exchange traded funds that WGS belongs to (by Net Assets): ARKK, VTI, IWM, ARKG, VXF.

WGS has underperformed the market in the last year with a return of -20.0%, while the SPY ETF gained +13.3%. In the last 3 month period, WGS fell short of the market, returning -33.4%, while SPY returned +4.0%. However, in the most recent 2 weeks WGS has outperformed the stock market by returning +5.9%, while SPY returned +1.4%.

WGS support price is $86.40 and resistance is $94.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WGS shares will trade within this expected range on the day.